bioRxiv · 10.1101/730572
Silencing epigenetic writer DOT1L attenuates intimal hyperplasia
Abstract
ObjectiveHistone methyltransferases are emerging targets for epigenetic therapy. DOT1L (disruptor of telomeric silencing 1-like) is the H3K79 methylation writer. We investigated its role in the development of intimal hyperplasia (IH).\n\nApproach and ResultsIH was induced via balloon angioplasty in rat carotid arteries. DOT1L and its catalytic products H3K79me2 and H3K79me3 (immunostaining) increased by 4.69 {+/-}0.34, 2.38 {+/-}0.052, and 3.07 {+/-}0.27 fold, respectively, in injured (versus uninjured) carotid arteries at post-injury day 7. DOT1L silencing via shRNA-lentivirus infusion in injured arteries reduced DOT1L, H3K79me2, and IH at day 14 by 54.5%, 37.1%, and 76.5%, respectively. Moreover, perivascular administration of a DOT1L-selective inhibitor (EPZ5676) reduced H3K79me2, H3K79me3, and IH by 56.1%, 58.6%, and 39.9%, respectively.\n\nConclusionsDOT1L inhibition mitigates the development of IH.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Huang, Y., Urabe, G., Zhang, M., Li, J., Wang, B., Kent, K. C., Guo, L.. 2019-08-09. Silencing epigenetic writer DOT1L attenuates intimal hyperplasia. https://doi.org/10.1101/730572
Cite the original work for its findings. Save a collection to share your selection of sources.